Literature DB >> 7525168

Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.

S Naveau1, T Poynard, C Benattar, P Bedossa, J C Chaput.   

Abstract

Alpha-2-macroglobulin (A2M) is a proteinase inhibitor. Cells synthesizing A2M are in first-order hepatocytes and in second-order activated Ito cells (in culture starting at day 4-5 after seeding). This study was undertaken in 525 alcoholic patients with different histological stages of alcoholic liver disease to assess if the A2M could improve the diagnostic value of PGA index for detection of cirrhosis or fibrosis among drinkers, particularly in patients without clinical symptoms of liver failure and portal hypertension, and to assess the specific correlation of serum A2M with the score of liver fibrosis adjusted for steatosis and alcoholic hepatitis and thereafter adjusted for GGT, PT, and ApoA1, the three components of the PGA index. In 525 alcoholic patients, we have demonstrated the independent diagnostic value of A2M. The predictive values of the weighted score, using linear discriminant function combining PT, GGT, ApoA1 and A2M of the PGAA score and of the PGA score were assessed in a training step and validated in a second step. Then, 316 alcoholic clinically asymptomatic patients were studied. In these patients, the discriminant function permitted correct classification of 72% of patients. The PGAA index had comparable diagnostic value with 70% of patients correctly classified. On the other hand, the PGA index including only PT, GGT, and ApoA1 had classified correctly less patients (65%) than the discriminant function and the PGAA index (P < 0.01). For a value of 7, PGAA had 79% specificity and 89% sensitivity for the diagnosis of cirrhosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525168     DOI: 10.1007/bf02087661

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Measurement of proteins with the Behring Nephelometer. A multicentre evaluation.

Authors:  P C Fink; M Römer; R Haeckel; A Fateh-Moghadam; J Delanghe; A M Gressner; R W Dubs
Journal:  J Clin Chem Clin Biochem       Date:  1989-04

2.  Tumor necrosis factor, the acute phase response and the pathogenesis of alcoholic liver disease.

Authors:  D L Thiele
Journal:  Hepatology       Date:  1989-03       Impact factor: 17.425

3.  Quantitative immunoelectrophoresis of serum proteins in cryptogenic cirrhosis, alcoholic cirrhosis and active chronic hepatitis.

Authors:  I M Murray-Lyon; H G Clarke; K McPherson; R Williams
Journal:  Clin Chim Acta       Date:  1972-06       Impact factor: 3.786

4.  Sensitive radioimmunoassays for 7 S collagen and laminin: application to serum and tissue studies of basement membranes.

Authors:  J Risteli; H Rohde; R Timpl
Journal:  Anal Biochem       Date:  1981-05-15       Impact factor: 3.365

5.  [Abnormalities of ten plasma proteins in alcoholic liver disease (author's transl)].

Authors:  B Nalpas; J M Boigné; E S Zafrani; R Zimmermann; P Berthelot
Journal:  Gastroenterol Clin Biol       Date:  1980-10

6.  Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients.

Authors:  P Bedossa; T Poynard; A Abella; A Aubert; J P Pignon; S Naveau; R Leluc; G Lemaigre; E D Martin; J C Chaput
Journal:  Alcohol Clin Exp Res       Date:  1989-12       Impact factor: 3.455

7.  Cell types involved in collagen and fibronectin production in normal and fibrotic human liver.

Authors:  B Clement; J A Grimaud; J P Campion; Y Deugnier; A Guillouzo
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

8.  Simultaneous measurement of plasma apolipoproteins A-I and B by electroimmunoassay.

Authors:  J C Fruchart; I Kora; C Cachera; V Clavey; P Duthilleul; Y Moschetto
Journal:  Clin Chem       Date:  1982-01       Impact factor: 8.327

9.  Physical and chemical properties of human plasma alpha2-macroglobulin.

Authors:  P K Hall; R C Roberts
Journal:  Biochem J       Date:  1978-07-01       Impact factor: 3.857

Review 10.  Effects of cytokines on the liver.

Authors:  T Andus; J Bauer; W Gerok
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

View more
  36 in total

1.  Thrombocytemia as a predictor of portal hypertension in schistosomiasis.

Authors:  M R Souza; C F Toledo; D R Borges
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

2.  "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C.

Authors:  Shoukat Ali Arain; Qamar Jamal; Amir Omair
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

3.  A new index for non-invasive assessment of liver fibrosis.

Authors:  Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Arima; Hiroaki Shimazaki; Koji Suzuki; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

4.  Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis.

Authors:  Dariusz Marek Lebensztejn; Elzbieta Skiba; Jolanta Tobolczyk; Maria Elzbieta Sobaniec-Lotowska; Maciej Kaczmarski
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 5.  Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched.

Authors:  M Pinzani
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

6.  Effective use of FibroTest to generate decision trees in hepatitis C.

Authors:  Dana Lau-Corona; Luís Alberto Pineda; Héctor Hugo Avilés; Gabriela Gutiérrez-Reyes; Blanca Eugenia Farfan-Labonne; Rafael Núñez-Nateras; Alan Bonder; Rosalinda Martínez-García; Clara Corona-Lau; Marco Antonio Olivera-Martínez; Maria-Concepción Gutiérrez-Ruiz; Guillermo Robles-Díaz; David Kershenobich
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

7.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

Review 8.  Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

Authors:  Rosa Lombardi; Elena Buzzetti; Davide Roccarina; Emmanuel A Tsochatzis
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.

Authors:  Dieter Vanderschaeghe; Wouter Laroy; Erwin Sablon; Philippe Halfon; Annelies Van Hecke; Joris Delanghe; Nico Callewaert
Journal:  Mol Cell Proteomics       Date:  2009-01-29       Impact factor: 5.911

10.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.